Whalesbook
Open Offer Launched for Rekvina Laboratories
Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel have formally announced an open offer for Rekvina Laboratories Limited. The individuals aim to acquire up to 28,90,100 equity shares, representing 25.92% of the company's total equity. The offer price is set at ₹10 per share, with the total transaction valued at ₹2.89 crore. To demonstrate commitment, the acquirers have deposited ₹0.72 crore, or 25% of the offer value, into an escrow account.
Significance for Shareholders
This open offer provides Rekvina Laboratories' public shareholders an exit opportunity at ₹10 per equity share. The transaction signals a potential shift in the company's ownership structure and may lead to the consolidation of shareholding by the Shah and Patel families, potentially establishing them as new promoters.
Background of the Deal
The open offer is part of a larger corporate transaction. It stems from a preferential issue of equity shares to the same individuals and follows a Share Purchase Agreement (SEPA) that initiated changes in promoter shareholding. Rekvina Laboratories is an Indian pharmaceutical company focused on manufacturing and marketing pharmaceutical formulations.
Shareholder Action and Potential Outcomes
Public shareholders have the option to tender their shares during the offer period. If successful, the acquirers could become significant stakeholders, influencing the company's future strategy and potentially leading to changes in the board composition.
Conditions and Risks
The open offer is subject to securing necessary statutory and regulatory approvals. The offer could be withdrawn if these approvals are denied or if conditions of the underlying SEPA are not met, provided these are beyond the acquirers' control. Delays in approvals might extend the offer period, and under certain conditions, could trigger interest payment obligations. However, willful default by the acquirers could result in the forfeiture of the escrow account funds.
Key Dates
- Offer Opening: May 13, 2026
- Offer Closing: May 27, 2026
- Last Date for SEBI Final Report: June 28, 2026
What to Track Next
Investors should monitor the progress of obtaining required statutory and regulatory approvals. The success of the share tendering process by public shareholders will also be critical. Additionally, payment of consideration to tendering shareholders, the final SEBI report filing, and any future announcements from the new stakeholders regarding post-offer plans will be important.